0001609351-17-000102.txt : 20170911 0001609351-17-000102.hdr.sgml : 20170911 20170911161548 ACCESSION NUMBER: 0001609351-17-000102 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170907 FILED AS OF DATE: 20170911 DATE AS OF CHANGE: 20170911 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Faga Daniel CENTRAL INDEX KEY: 0001673528 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36819 FILM NUMBER: 171079156 MAIL ADDRESS: STREET 1: 3737 MARKET STREET STREET 2: SUITE 1300 CITY: PHILADELPHIA STATE: PA ZIP: 19104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Spark Therapeutics, Inc. CENTRAL INDEX KEY: 0001609351 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 462654405 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3737 MARKET STREET STREET 2: SUITE 1300 CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: 888-772-7560 MAIL ADDRESS: STREET 1: 3737 MARKET STREET STREET 2: SUITE 1300 CITY: PHILADELPHIA STATE: PA ZIP: 19104 4 1 wf-form4_150516093442742.xml FORM 4 X0306 4 2017-09-07 0 0001609351 Spark Therapeutics, Inc. ONCE 0001673528 Faga Daniel 3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104 0 1 0 0 Chief Business Officer Common Stock 2017-09-07 4 M 0 3000 37.62 A 3000 D Common Stock 2017-09-07 4 S 0 1500 85 D 1500 D Common Stock 2017-09-07 4 S 0 1500 85.03 D 0 D Employee Stock Option (right to buy) 37.62 2017-09-07 4 M 0 3000 0 D 2026-05-01 Common Stock 3000.0 145000 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.04, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. 25% vested May 2, 2017 and the remainder vests in equal quarterly installments over the following three years. /s/ Joseph W. La Barge, attorney-in-fact for Daniel R. Faga 2017-09-11